Vivace Therapeutics, Inc., a San Mateo, CA-based small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, closed a $30m Series C financing.
The round was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. In conjunction with the funding, Dr. Norman Zhou of Boxer Capital joined the board of directors at Vivace.
The company intends to use the funds to advance its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP.
Led by Sofie Qiao, Ph.D., President and Chief Executive Officer, Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing several first-in-class drug candidates to treat human carcinomas of high unmet medical need. .
Its compounds inhibit palmitoylation of members of the transcriptional enhanced associate domain (TEAD) protein family. Pre-clinical research and development activities show that the clinical candidate is active as a monotherapy and in combination with other anti-cancer therapies against tumors that rely upon dysfunction of the Hippo pathway.